Ironwood Pharmaceuticals rose 30% after a strategic price cut on Linzess unlocked higher revenue guidance and surprised Wall ...

Rigel Pharmaceuticals recently issued full-year 2026 guidance, projecting total revenue of about US$275 million to US$290 ...

Pablo Gerardo Legorreta, CEO, highlighted "a successful quarter of execution" with "20% growth in Portfolio Receipts, our top line to $727 million, an 11% growth in Royalty Receipts to $672 million." ...

ANI Pharmaceuticals, Inc. delivered robust 2025 results and issued bullish 2026 guidance. Learn more about ANIP stock here.

Royalty Pharma reports Q1 2025 financials with 17% portfolio receipts growth, raising 2025 guidance to $2,975-$3,125 million. Royalty Pharma plc announced its financial results for the first quarter ...

What Happened? Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) jumped 13.6% in the afternoon ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

On Thursday, West Pharmaceutical Services, Inc. (NYSE:WST) reported a fourth-quarter adjusted EPS of $1.82, beating the consensus of $1.72. The designer and manufacturer of injectable pharmaceutical ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported first-quarter earnings of 16 cents per share, compared to a loss of 7 cents a year ago. This beat the consensus of 10 cents. The biopharma company ...

Royalty Pharma increased its portfolio receipts 20% year over year in the second quarter of 2025, announced a partnership with Revolution Medicines worth up to $2 billion, and completed an acquisition ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

For pharmaceutical marketers, the pharmacy relationship is as powerful as it is underutilised. Rather than focusing outreach ...